What Is the AngioVac System and How Does It Work?

The AngioVac is a catheter-based suction device designed to pull blood clots, infected material, and other unwanted masses out of the heart and large veins without open surgery. It works by threading a large-bore cannula through a vein, vacuuming up the problematic material, filtering the blood, and returning it to the body through a second vein. The device fills a specific niche: patients who have dangerous clots or growths in the right side of the heart or the major veins but who are too sick or too high-risk to survive a traditional surgical approach.

How the Device Works

The AngioVac system is built around a venovenous extracorporeal circuit, which means it pulls blood out of one vein, runs it through an external loop, and sends it back into another vein. The key component is a coil-reinforced cannula with a balloon-actuated, funnel-shaped tip at the end. When that balloon inflates, the tip fans open like a small umbrella, creating a wide mouth that can capture clots and masses as the circuit’s pump generates suction. Blood and debris travel through the cannula into an external circuit that includes a centrifugal pump, a filter, and a bubble trap. The filter catches the solid material while cleaned blood flows back into the patient through a separate return cannula placed in another vein.

1Journal of Cardiothoracic and Vascular Anesthesia. Perioperative Outcomes of Thrombectomy Patients Using Venovenous Bypass and Suction Filtration With General Anesthesia

Think of it as a tiny, specialized bypass machine. The concept borrows heavily from cardiopulmonary bypass technology used in open-heart surgery, but scaled down and focused specifically on removing unwanted material rather than keeping the whole body oxygenated while the heart is stopped.

2PubMed Central. Use of a Modified Cardiopulmonary Bypass Circuit for Suction Embolectomy with the AngioVac Device

The circuit is not one-size-fits-all. One single-center series of 44 patients described three configurations: a standard vein-to-vein circuit used in about half of cases, an ECMO-like vein-to-artery setup used in nearly as many, and a more complex two-pump circuit reserved for the rare situation where a mass sits on the left side of the heart. The choice of configuration depends on where the clot is, how hemodynamically unstable the patient is, and whether the team needs the circuit to provide broader circulatory support during the procedure.

3Elsevier / PubMed Central. Navigating the Heart. The Evolution of the AngioVac System in a Single-center Experience

What the AngioVac Is Used For

The device was designed for soft thrombus and emboli in the venous system, meaning the right side of the heart, the inferior and superior vena cava, and the pulmonary arteries. In practice, the most common targets fall into a few categories:

Hemodialysis patients represent another group that may benefit. Large catheter-related thrombi attached to tunneled dialysis catheters can be difficult to manage with medication alone, especially in patients who are already at high bleeding risk or who have failed thrombolytic therapy. The AngioVac offers a mechanical alternative for evacuating these clots.

6IntechOpen. Hemodialysis Vascular Access with Central Venous Disease

A recurring theme across all these indications is that the AngioVac tends to be reserved for patients who are poor candidates for open surgery. In a case series of four patients with right heart thrombi or tricuspid valve vegetations, all were considered high surgical risk, and the device served as a less invasive path to removing the dangerous material.

7PubMed. Aspiration of Right Sided Intracardiac Masses in High-Risk Surgical Patients Using AngioVac: A Case Series and Review of Literature

How the Procedure Is Performed

An AngioVac procedure happens in a hybrid operating room or catheterization lab under general anesthesia. The team typically includes an interventional cardiologist or vascular surgeon, a cardiac surgeon, a perfusionist to manage the extracorporeal circuit, and an anesthesiologist running real-time imaging.

Access usually involves two large veins, most often the femoral veins in the groin or the internal jugular vein in the neck. The aspiration side requires a large-bore sheath, commonly 26 French, to accommodate the AngioVac cannula itself. The return side uses a smaller cannula, typically around 16 French. Both guidewires and cannula positions are confirmed using fluoroscopy and, increasingly, transesophageal echocardiography, which gives the team a live picture of the heart’s chambers.

8PubMed Central. AngioVac Procedures: Integration of cardiac surgeon and anesthesiologist-led transesophageal echocardiography: A preliminary report

Once the cannula is in position near the target mass, the pump is engaged and suction begins. The operator steers the funnel-tipped cannula toward the clot or vegetation under image guidance, attempting to capture as much material as possible. The filtered blood returns to the patient continuously, so the body’s circulating volume stays relatively stable throughout the procedure. In some cases, the team will make multiple passes to maximize debulking.

The dual-imaging approach matters. Fluoroscopy shows the cannula’s position in real time, but transesophageal echocardiography reveals the mass itself, how much has been removed, and whether the cannula is close enough to cardiac structures to risk damage. Integrating both gives the team substantially better situational awareness than either modality alone.

How Effective Is It

Success rates vary depending on where the mass is located and how success is defined. In an early 16-case series, procedural success was 100% for clots in the vena cava but lower for right atrial masses, at about two-thirds. All patients with caval thrombus who presented with limb swelling had improvement or complete resolution of their symptoms.

9Elsevier / PubMed Central. Removal of Caval and Right Atrial Thrombi and Masses Using the AngioVac Device: Initial Operative Experience

A larger single-center experience of 44 patients reported successful removal of the mass in about 93% of cases, with the remaining patients requiring conversion to open surgery through a full sternotomy.

10Elsevier / PubMed Central. Navigating the Heart. The Evolution of the AngioVac System in a Single-center Experience

For endocarditis specifically, one study of 33 patients defined success as reducing the vegetation by more than half without severe intraoperative complications or the need for subsequent valve surgery. By that measure, the procedure succeeded in 85% of cases.

11PubMed Central. Effectiveness of the vacuum assisted aspiration AngioVac system in the removal of intravascular masses

Another small series focused on debulking vegetations from infected pacemaker leads before extraction reported that all patients had successful debulking with no procedural complications and no deaths within 30 days.

12European Heart Journal – Case Reports. Use of AngioVac device in debulking endocarditis vegetations before lead extractions

The picture that emerges is that AngioVac works well for elongated clots in the vena cava and for reducing the bulk of large vegetations, but it is less reliable for masses that are broad-based or firmly attached to cardiac structures. The device excels at suctioning soft, mobile material and struggles more when the target is organized, calcified, or adherent.

Risks and Complications

The AngioVac is less invasive than open-heart surgery, but it is not a gentle procedure. The large-bore venous access, the extracorporeal circuit, and the suction forces all carry real risks.

Blood loss is the most predictable issue. In the 14-patient series, nearly three-quarters of patients had a drop in blood counts after the procedure, though only two cases involved access-site bleeding that required transfusion.

13PubMed. Thrombectomy using suction filtration and veno-venous bypass: single center experience with a novel device In the 33-patient endocarditis series, nearly half of patients needed a blood transfusion afterward.

14PubMed Central. Effectiveness of the vacuum assisted aspiration AngioVac system in the removal of intravascular masses

Hemodynamic instability during and after the procedure is common. That same endocarditis study found that nearly all patients required vasopressor medications to maintain blood pressure during the operation, and about 40% continued to need them afterward. Almost all patients were sent to the intensive care unit, with a median stay of roughly a week. Other complications included fluid accumulation around the lungs in about a quarter of patients and sepsis in roughly one in eight.

15PubMed Central. Effectiveness of the vacuum assisted aspiration AngioVac system in the removal of intravascular masses

Serious structural complications are less frequent but can be catastrophic. In the 44-patient single-center series, intraoperative complications occurred in about 7% of cases, including one death, one episode of pulmonary embolization during the procedure, and one cardiac perforation.

16Elsevier / PubMed Central. Navigating the Heart. The Evolution of the AngioVac System in a Single-center Experience

Context matters when interpreting these numbers. The patients receiving AngioVac procedures are typically very sick to begin with. In the 14-patient early experience, more than a quarter were in cardiogenic shock at the start of the case, and in-hospital mortality was 13%, though no deaths occurred during the procedure itself and there were no strokes, heart attacks, or pulmonary hemorrhages.

17PubMed. Thrombectomy using suction filtration and veno-venous bypass: single center experience with a novel device

How AngioVac Compares to Alternatives

Open surgical thrombectomy or valve surgery remains the gold standard for removing large intracardiac masses and is the most reliable way to achieve complete removal. But it requires sternotomy, cardiopulmonary bypass, and often a prolonged ICU recovery. For patients who are too frail, too hemodynamically unstable, or have too many comorbidities, AngioVac offers a percutaneous alternative that avoids cracking the chest.

Among catheter-based devices, the AngioVac’s main distinguishing feature is also its biggest logistical burden: the extracorporeal circuit. Newer devices like the FlowTriever can perform mechanical thrombectomy without requiring a separate bypass circuit, making them simpler to set up and potentially less invasive.

18PubMed Central. Emergent mechanical thrombectomy for right atrial clot and massive pulmonary embolism using flowtriever That circuit requirement means every AngioVac case needs a perfusionist on hand and a room equipped to run extracorporeal circulation, which limits where the procedure can be performed and adds cost and personnel demands.

The tradeoff is suction power and versatility. Because the AngioVac uses a dedicated pump and filter system, it can handle larger volumes of material and process the aspirated blood for return to the patient, rather than simply pulling clot out and discarding the blood that comes with it. For large, bulky vegetations or extensive thrombus burden, that sustained suction capacity can be an advantage.

For cancer patients specifically, one study comparing outcomes in 20 patients with active malignancy to 24 without found no meaningful difference in survival or technical success between the two groups, despite the cancer patients being sicker overall. This suggests the device performs comparably regardless of cancer status, which is relevant because cancer patients frequently develop catheter-related clots and are often considered high risk for open surgery.

19Annals of Vascular Surgery / Elsevier. AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients

Use in Children

The AngioVac was designed for adult vasculature, and the large-bore cannulas are a significant constraint in smaller patients. The device is not routinely used in children. But a handful of reports have described successful use in pediatric patients when the clinical situation was desperate enough to justify the attempt.

One case involved a 10-year-old child weighing just 23 kilograms with a failing Fontan circulation, a type of surgical repair for complex congenital heart disease. The child had acute-on-chronic clot in the Fontan pathway and pulmonary arteries. The team used modified AngioVac components alongside a vein-to-artery ECMO circuit, running both through a single pump. Enough clot was removed to stabilize the child, who came off ECMO within 24 hours and went home less than a month later.

20ASAIO Journal. Modified AngioVac System use With Extracorporeal Membrane Oxygenation in a Child With Fontan Thrombosis

A second report described two pediatric patients, a 10-year-old girl and a 17-year-old boy, both of whom had concurrent low oxygen levels. The team combined the AngioVac with venovenous ECMO to remove caval thrombi in one case and infected material extending from the vena cava into the right atrium in the other. Both procedures were successful.

21ASAIO Journal. The AngioVac System in Childhood and Adolescence: A New Venovenous Extracorporeal Membrane Oxygenation-Like Configuration

These cases required significant circuit modifications and close monitoring. The authors of the Fontan case explicitly noted that while the approach is feasible, it demands experienced teams comfortable with both congenital heart physiology and extracorporeal circuit management. Pediatric use remains off-label and case-by-case.

Recurrence After the Procedure

One of the less-discussed realities of AngioVac thrombectomy is that removing the clot or vegetation does not always mean the problem stays away. In the early operative experience that tracked patients after discharge, about one in five cases with initially successful procedures had local recurrence of the mass or thrombus, at an average of roughly two months after the intervention.

22Elsevier / PubMed Central. Removal of Caval and Right Atrial Thrombi and Masses Using the AngioVac Device: Initial Operative Experience

That recurrence rate makes sense when you consider what the device does and does not do. The AngioVac removes the physical mass, but it does not treat the underlying reason the mass formed. If the patient has ongoing endocarditis with bacteria still seeding the bloodstream, debulking a vegetation buys time for antibiotics to work but does not cure the infection on its own. If a patient forms clot because of an indwelling catheter, hypercoagulability from cancer, or stasis in the vena cava, the conditions for re-clotting persist after the procedure. Anticoagulation, antimicrobial therapy, and addressing the root cause all remain essential after the device has done its part.

The Role of Endocarditis Debulking

Endocarditis represents one of the more compelling and debated uses of the AngioVac. Standard treatment for infected heart valve vegetations is weeks of intravenous antibiotics, sometimes followed by surgery to repair or replace the damaged valve. But surgery carries substantial mortality in patients who are actively septic, and some patients simply cannot survive the operation.

The idea behind using the AngioVac in endocarditis is not to cure the infection but to reduce the bacterial load and vegetation bulk enough to lower the risk of large septic emboli breaking off and traveling to the lungs. This is especially relevant for tricuspid valve endocarditis, which predominantly affects people who inject drugs and is overwhelmingly a right-sided disease.

A study focused specifically on percutaneous debulking of tricuspid valve endocarditis found zero procedural complications across the cohort.

23PubMed. Outcomes With Percutaneous Debulking of Tricuspid Valve Endocarditis The lead extraction series showed similar safety, with all patients achieving successful vegetation debulking before their infected pacemaker leads were removed, and no deaths within 30 days.

24European Heart Journal – Case Reports. Use of AngioVac device in debulking endocarditis vegetations before lead extractions

The evidence here is still built on small case series rather than randomized trials, and the field has not reached consensus on exactly which endocarditis patients benefit most from debulking versus going straight to surgery or prolonged antibiotics alone. But for patients who are poor surgical candidates and have large, mobile vegetations threatening to embolize, the AngioVac has carved out a role as a bridge therapy: reducing immediate danger while medical treatment continues.

What the Evidence Still Lacks

Nearly everything known about AngioVac performance comes from single-center case series and retrospective reviews, mostly with patient counts in the teens to low forties. There are no randomized controlled trials comparing the device head-to-head with surgical thrombectomy, medical management alone, or competing catheter-based systems. The published literature is dominated by centers that have developed particular expertise with the device, which likely inflates the reported success rates compared to what a less experienced team might achieve.

The absence of standardized outcome definitions makes comparing studies difficult. Some define success as complete removal, others as more than 50% reduction, and others as symptom resolution. Complication reporting is similarly inconsistent. The 33-patient endocarditis study documented vasopressor-dependent shock in 39% of patients post-procedure, while the tricuspid debulking study reported zero complications. Whether those differences reflect different patient populations, different operators, or different thresholds for what counts as a complication is impossible to say without standardized registries.

What is clear is that the device occupies a genuine clinical niche. For patients with large intravascular or intracardiac masses who cannot tolerate open surgery, the AngioVac offers a percutaneous option that has demonstrated feasibility across hundreds of reported cases. The challenge going forward is generating the comparative data that would help clinicians know which patients benefit most, and which might do better with newer, simpler thrombectomy platforms that do not require an extracorporeal circuit.